International Journal of Endocrinology / 2017 / Article / Tab 1

Research Article

Comparison of Exenatide and Metformin Monotherapy in Overweight/Obese Patients with Newly Diagnosed Type 2 Diabetes

Table 1

Baseline characteristics of the exenatide and metformin groups.

ParametersExenatide ()Metformin ()

Age, y45.77 ± 10.6048.05 ± 8.040.097
Gender, males/females, n64/4671/490.880
Overweight/obesity, n57/5363/570.918
Body weight, kg78.76 ± 10.0177.98 ± 11.880.907
BMI, kg/m227.83 ± 2.3827.57 ± 3.560.815
TC, mmol/L5.21 ± 1.255.29 ± 1.220.664
LDL-C, mmol/L3.07 ± 0.893.05 ± 0.900.864
HDL-C, mmol/L1.12 ± 0.431.24 ± 0.290.087
TG, mmol/L2.07 (1.27–3.99)1.93 (1.32–2.75)0.235
FBG, mmol/L9.34 ± 3.279.10 ± 1.340.594
FINS, μIU/mL9.50 (5.98–14.37)10.14 (5.25–14.94)0.337
HbA1c, %9.11 ± 1.469.03 ± 1.180.230
HOMA-IR3.94 (2.47–5.93)3.87 (2.27–6.02)0.638
HOMA-β55.13 (29.64–76.65)50.55 (29.80–74.81)0.289

Data are means ± SD unless indicated otherwise. TG, FINS, HOMA-IR, and HOMA-β are shown as medians (upper and lower quartiles). BMI: body mass index; TC: total cholesterol; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; TG: triglyceride; FBG: fasting blood glucose; FINS: fasting insulin; HOMA-IR: homeostasis model assessment of insulin resistance; HOMA-β: homeostasis model assessment of β-cell function.